Goodwill and Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Carrying Value of Goodwill

The carrying values of goodwill assigned to the Company’s operating segments are as follows:

	Cell Therapy			Biobanking		Degenerative Disease		Total
Balance at December 31, 2022	$	112,347		$	7,347	$	-	$	119,694
Impairment(1)		(112,347	)		-		-		(112,347	)
Balance at September 30, 2023	$	-		$	7,347	$	-	$	7,347

(1) As of September 30, 2023 and December 31, 2022, the accumulated goodwill impairment for the Degenerative Disease reporting unit was $3,610 and for Cell Therapy the accumulated goodwill impairment was $112,347 and $0 as of September 30, 2023 and December 31, 2022, respectively.

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

	September 30, 2023			December 31, 2022			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11-16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10-13 years
Reacquired rights		4,200			4,200		6 years
		23,993			23,993
Less: Accumulated amortization
Developed technology		(7,427	)		(6,549	)
Customer relationships		(1,633	)		(1,435	)
Trade names & trademarks		(316	)		(275	)
Reacquired rights		(3,763	)		(3,240	)
		(13,139	)		(11,499	)
Amortizable intangible assets, net		10,854			12,494
Non-amortized intangible assets
Acquired IPR&D product rights		700			108,500		indefinite
	$	11,554		$	120,994